Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
UK to hold fresh pork, other affected Spanish products at border amid African swine fever outbreak - 2Aluminum salts emerge as likely target as health officials scrutinize childhood vaccines
- 3An Extended period of Voyaging Carefully: the World with Reason
- 4What's Your Number one Superhuman Film Made?
- 5CDC's upcoming vote on hepatitis B vaccine could impact childhood immunization
- Which Switch Game Do You Suggest? Share Your Decision
- Hilary Duff releases 'Mature,' her 1st song in 10 years
- Kiefer Sutherland arrested after allegedly assaulting a ride-share driver in L.A.
- Figuring out the Justification for Separation: To blame and No-Shortcoming
- Blue Origin launches huge rocket carrying twin NASA spacecraft to Mars
- 2024 Moving Styles for Kitchen Redesigns
- Soldiers seize power in Guinea-Bissau and detain the president
- German politician urges more face-to-face interaction in digital age
- This Week In Space podcast: Episode 188 — A New NASA Leader Rises?
